Magnetic Resonance Imaging Repercussions of Intravenous Iron Products Used for Iron-Deficiency Anemia and Dialysis-Associated Anemia
Authors:
- Guy RostokerGuy Rostoker
- Yves CohenYCYves Cohen
- 1 January 2014
- journal article
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
- Vol. 38 (6) , 843-844
Abstract
During the past 2 decades, routine use of recombinant erythropoiesis-stimulating agents (ESAs) has enabled anemia to be corrected in dialysis patients, thereby improving their quality of life and permitting better outcomes. As successful use of ESA requires sufficient available iron, almost all end-stage renal disease patients on ESA now receive concomitant parenteral iron therapy. Radiologists must be aware that iron overload among dialysis patients is now an increasingly recognized clinical situation in the ESA era yet was previously considered rare. The KDIGO Controversies Conference on Iron Management in Chronic Kidney Disease, which took place in San Francisco on March 27 to 30, 2014, recognized the entity of iron overload in hemodialysis patients and called for an agenda of research on this topic, especially by means of magnetic resonance imaging (MRI).It is therefore very likely that radiologists will be heavily solicited in the future by nephrology teams requesting quantitative hepatic MRI in dialysis patients, both for research purposes and for diagnosis and follow-up of iron overload. Radiologists should be aware of the marked differences in the pharmacological properties of available intravenous iron products and their potential interference with MRI. Specific MRI protocols need to be established in radiology divisions for each pharmaceutical iron product, especially for treated dialysis patients.Keywords
This publication has 8 references indexed in Scilit:
- The Long-Lasting Effect of Ferumoxytol on Abdominal Magnetic Resonance ImagingJournal of Computer Assisted Tomography, 2014
- Bone marrow uptake of ferumoxytol: A preliminary study in healthy human subjectsJournal of Magnetic Resonance Imaging, 2013
- MRI Assessment of Hepatic Iron Clearance Rates After USPIO Administration in Healthy AdultsInvestigative Radiology, 2012
- Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: A MRI StudyThe American Journal of Medicine, 2012
- The Pharmacokinetics and Pharmacodynamics of Iron PreparationsPharmaceutics, 2011
- Pharmacokinetics and red cell utilization of 52Fe/59Fe‐labelled iron polymaltose in anaemic patients using positron emission tomographyBritish Journal of Haematology, 2003
- Kinetic analysis of 52Fe‐labelled iron(III) hydroxide–sucrose complex following bolus administration using positron emission tomographyBritish Journal of Haematology, 1999
- Pharmacokinetics and red cell utilization of iron(III) hydroxide–sucrose complex in anaemic patients: a study using positron emission tomographyBritish Journal of Haematology, 1999